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pancreaticoduodenectomy for malignancy based on
tumour site, stage and lymph node ratio
Bobby V.M. Dasari1, Keith J. Roberts1, James Hodson2, Lewis Stevens3, Andrew M. Smith3,
Stefan G. Hubscher4, John Isaac1, Paolo Muiesan1, Robert P. Sutcliffe1, Ravi Marudanayagam1
& Darius F. Mirza1
1Department of HPB Surgery, 2Institute of Translational Medicine, Queen Elizabeth Hospital, Birmingham, B15 2TH, 3Leeds Teaching
Hospitals, Leeds, and 4Department of Cellular Pathology, Queen Elizabeth Hospital, Birmingham, B15 2WB, UKAbstract
Background: Site of tumour origin, lymph node metastases and lymph node ratio (LNR) are identified
as important factors determining prognosis in patients undergoing pancreaticoduodenectomy (PD). This
study hypothesised that a prognostic index to predict survival could be developed through statistical
modelling based on these pathological variables.
Methods: Patients who underwent PD between 2004 and 2013 were included. Univariable and multi-
variable (Cox regression) analyses were performed to identify predictors of survival, and a prognostic
index was derived. The prognostic index was then validated using an external patient cohort.
Results: A total of 567 patients who underwent PD were used as a derivation cohort. Tumour site
(p < 0.001), tumour size (p = 0.002), T-stage (p < 0.001), vascular involvement (p = 0.002), number of
positive nodes (p < 0.001) and LNR (p < 0.001) were significantly associated with survival in univariable
analysis. LNR (p < 0.001), tumour site (p < 0.001), T-stage (p = 0.007) remained significant predictors of
survival in multivariable analysis, and were combined to derive a prognostic index. The accuracy of the
prognostic index was assessed both on the original cohort, and a validation set of 194 patients from
another institutional prospective database. The AUROC scores for predicting the overall survival at 3
years were 0.77 in the derivation cohort and 0.74 in the validation cohort.
Conclusion: The Pancreaticoduodenectomy Prognostic Index is a validated clinico-pathological model
based on tumour site, T-stage and LNR to predict long-term survival following PD.Received 10 November 2015; accepted 20 November 2015Correspondence:
Darius F. Mirza, The HPB and Transplantation Unit, Queen Elizabeth Hospital, Edgbaston, Birmingham,
B15 2WB, UK. Tel: +44 1213714638. Fax: +44 1214141833. E-mail: darius.mirza@uhb.nhs.ukIntroduction
Surgical resection remains the only potentially curative treatment
for patients with adenocarcinomas arising from head of
pancreas, ampulla, distal bile duct and ampulla. Although the
median survival following pancreaticoduodenectomy (PD) has
improved,1 the actual five-year survival after resection of
pancreatic ductal adenocarcinoma approaches 10%.2–5 For
ampullary carcinoma and distal cholangiocarcinoma, 5-yearThis study was presented at the AUGIS Scientific Meeting, 18–19
September 2014, Brighton.
HPB 2016, 18, 332–338 © 2016 International Hepato-Psurvival varies between 20 and 40%6,7 and is up to 60% for
duodenal adenocarcinoma.8 Various factors, however, impact
upon cancer related outcomes after PD, including tumour site,
tumour size, tumour at the resection margins, lymph node
metastases, and histologic grade.3,9–11 The role of post-operative
chemotherapy/radiotherapy continues to evolve and can increase
survival.12–14
The presence of nodal metastases has been shown to be an in-
dicator of poor prognosis.3–5,15,16 Evidence suggests that a mini-
mumof 11–15 lymphnodes (LNs) should be examined to provide
an accurate assessment of LN metastases upon which to baseancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.
Table 1 Association between clinico-pathological factors and pa-
tient survival (derivation cohort)
N Overall survival
1 year, 3 years
p-Value
Age 0.074
<60 149 (26%) 74%, 37%
60–66 144 (25%) 71%, 38%
67–74 174 (31%) 66%, 30%
75+ 100 (18%) 65%, 32%
a
HPB 333prognostic information, following resection for pancreatic
cancer.17–19 The AJCC TNM staging system considers LN me-
tastases as a binary outcome – they are or are not present.20 Recent
studies have demonstrated that the lymph node ratio (number of
metastatic lymph nodes (LNs) divided by total number of exam-
ined nodes) provides additional prognostic information over the
standard reporting of LN metastasis and its role in pancreatic
carcinoma is also increasingly accepted.17,21,22 The aim of this
study was to develop a prognostic index that could be applied to
the four common tumour types that require PD.Smoking status 0.570
Never 135 (51%) 72%, 39%
Ex 87 (33%) 73%, 38%
Current 43 (16%) 71%, 31%
BMIa 0.528
<=25 157 (50%) 73%, 32%
26–30 114 (36%) 68%, 41%
31–35 30 (9%) 64%, 25%
>35 16 (5%) 65%, 55%
Tumour <0.001b
Ductal adenocarcinoma 279 (49%) 63%, 23%
Cholangiocarcinoma 89 (16%) 61%, 30%
Duodenal carcinoma 32 (6%) 77%, 60%
Ampullary carcinoma 167 (29%) 83%, 56%
Tumour size 0.002b
<2.0 85 (17%) 74%, 50%
2.0–2.4 88 (18%) 68%, 37%
2.5–3.4 167 (34%) 70%, 32%
3.5+ 148 (30%) 63%, 25%
T stage <0.001b
1 31 (6%) 86%, 82%
2 60 (11%) 88%, 74%
3 393 (75%) 67%, 28%
4 41 (8%) 71%, 29%
R status <0.001b
Negative 450 (80%) 80%, 38%
Positive 114 (20%) 58%, 22%
Vascular reconstruction 0.002b
No 493 (87%) 70%, 51%
Yes 74 (13%) 65%, 20%
Adjuvant chemotherapya 0.074
No 133 (48%) 67%, 41%
Yes 147 (52%) 82%, 40%
Any pre-op comorbidity 0.132
No 344 (61%) 76%, 34%
Yes 223 (39%) 59%, 36%
Wound infection 0.522Materials and methods
This was a retrospective analysis of a prospectively maintained
database of patients who underwent PD between 2004 and 2013.
Patients with pancreatic ductal carcinoma, distal chol-
angiocarcinoma, ampullary carcinoma or duodenal carcinoma
were included. Patients undergoing surgery for other pathologies
were excluded. Pylorus preserving PD was the standard opera-
tion, with a Kausch Whipple procedure performed when it was
deemed appropriate on oncological grounds. A standard
lymphadectomy was performed to include dissection of the
common hepatic artery from the splenic artery origin to the
origins of the hepatic arteries. Perineural tissue and lymph nodes
along the common bile duct, station 8 nodes along the hepatic
artery, posterior and anterior pancreatico-duodenal nodes,
nodes along the superior mesenteric vein and right lateral wall of
the superior mesenteric artery were removed. The technique of
pancreato-enteric anastomosis was performed at the operating
surgeons discretion. Patients received adjuvant chemotherapy in
line with existing practice within the United Kingdom at that
time following surgery.
All specimens were reviewed by dedicated pancreatic specialist
pathologists. The AJCC TNM system was used for staging the
tumour.20 Site of tumour origin was based on macroscopic
assessment of tumour location. Whenever possible, this was
corroborated by histological identification of in-situ neoplasia
(pan-IN for ductal adenocarcinoma, Bil-IN for chol-
angiocarcinoma). For the purposes of the present study, the
resection margins that were consistently examined were the
pancreatic neck transection margin, the superior mesenteric
artery surface, proximal bile duct margin, proximal duodenal
margin and distal duodenal margin. Verbeke’s description23,24 of
positive resection margin (tumour found within 1 mm of the
margin) was used for the patients included in the latter part of
the study period.
Outcomes assessed
Median follow up of the patients included in the study was 1.36
years (range, 0.02–10.05 years). Overall survival (OS) was
assessed, and reported at one and three years.No 523 (92%) 70%, 35%
(continued on next page)
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Table 2 Associations between LN related factors and patient sur-
vival in derivation cohort
N Overall survival
1 year, 3 years
p-Value
No. of nodes taken 0.592
1–15 149 80%, 36%
16–20 155 70%, 40%
21–25 125 70%, 31%
>25 114 69%, 34%
No. of positive nodes <0.001a
0 148 84%, 62%
1–2 132 72%, 35%
3–5 146 65%, 26%
>5 118 57%, 14%
LN ratio <0.001a
0.00 147 85%, 63%
0.01–0.15 142 74%, 38%
0.16–0.25 114 59%, 18%
>0.25 140 60%, 18%
Survival is reported as Kaplan–Meier estimates at 1 and 3 years, and p-
values are from Log-Rank tests based on all available follow-up.
a Significant at p < 0.05.
Table 1 (continued )
N Overall survival
1 year, 3 years
p-Value
Yes 43 (8%) 61%, 29%
Pancreatic leak 0.097
No 472 (83%) 72%, 35%
Grade A 57 (10%) 59%, 31%
Grade B 20 (4%) 63%, 30%
Grade C 17 (3%) 35%, 28%
Intra-abdominal collection 0.543
No 534 (94%) 70%, 35%
Yes 33 (6%) 57%, 37%
Survival is reported as Kaplan–Meier estimates at 1 and 3 years, and p-
values are from Log-Rank tests based on all available follow-up.
a Data only available post-2007.
b Significant at p < 0.05.
Table 3 Multivariable Cox regression model (derivation cohort)
Overall survival
B HR (95% CI) p-Value
Tumour 0.001a
Ductal adenocarcinoma 0.0 1 –
Cholangiocarcinoma 0.0 0.98 (0.73–1.33) 0.921
Duodenal carcinoma −1.4 0.25 (0.11–0.55) 0.001a
Ampullary carcinoma −0.5 0.61 (0.43–0.87) 0.007a
T stage 0.007a
1 −0.8 0.44 (0.19–1.06) 0.067
2 −0.9 0.41 (0.23–0.73) 0.002a
3 0.0 1 –
4 0.2 1.17 (0.72–1.88) 0.531
LNR 1.9 6.79 (3.85–11.99) <0.001a
Variables not in the final model
Tumour size 0.124
334 HPBStatistical analysis
Continuous variables were categorised into four groups, prior to
survival analysis, either using arbitrary cut-offs based on clinical
experience (BMI and age), or by rounding the quartiles to mean-
ingful values. The relationship between several clinico-
pathological factors, and OS were then assessed using Kaplan–
Meier curves, with Log–Rank tests. Factors found to be significant
in univariable analysis were then analysed using a multivariable
Cox regression model, with a forward stepwise entry method.
A prognostic index was then proposed based on the co-
efficients of Cox regression model. The Cox regression model
was then converted into a PPI. The coefficients from the model
(i.e. the logged hazard ratios) were rounded to the nearest 0.5,
after being multiplied by two, to reduce the effect of rounding
errors. Where this resulted in a negative value, a constant value
(three) was added to these coefficients, in order that the score
would be purely additive, and easier to use in practice. The
resulting score had a potential range from 1 to 10.5. The accuracy
of the prognostic index was assessed using ROC curves, both on
the derivation cohort, and a validation cohort, identified from a
prospectively maintained database from Leeds Teaching Hospi-
tals (January 2008–December2013). OS at both one and three
years were used as outcomes in the ROC analysis, with patients
with potential follow-up shorter than this being excluded from
the respective analyses.
All analyses and the statistical modelling were performed using
IBM SPSS 19 (IBM Corp. Armonk, NY), by a medical statistician
(JH).Missingdatawere excludedonaper analysisbasis, andp<0.05
was deemed to be indicative of statistical significance throughout.R status 0.715
Vascular reconstruction 0.535
HR, hazard ratio.
B = Coefficients of the Cox regression model (logged hazard ratios).
a
Results
A total of 567 patients were identified as the derivation cohort of
which 311 (55%) were male. Characteristics of patients andHPB 2016, 18, 332–338 © 2016 International Hepato-Passociation with survival of the patients in the derivation cohort
are provided in Table 1. There was no significant variation in the
yield of lymph nodes over the study period (p = 0.116) with
medians of 16 (quartiles: 13–24) in 2004, and 2115–26 in 2013.Significant at p < 0.05.
ancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.
HPB 335Association of lymph node variables with survival in the deri-
vation cohort are shown in Table 2. The correlation between the
number of positive nodes, and the LNR was extremely high
(Spearman coefficient = 0.955). Hence, to avoid issues with
multi-collinearity, only the LNR was used in subsequent analysis.
No significant association was detected between the number of
lymph nodes taken and OS (p = 0.592). A subgroup analysis
demonstrated significant relationship between the LNR and OS
in ductal adenocarcinoma and ampullary carcinoma (both
p < 0.001, Supplementary Fig. 1). The relationship between LNR
and OS was close to significance in cholangiocarcinoma
(p = 0.059), and non-significant in duodenal carcinoma
(p = 0.610), but the numbers of patients in these groups was
small, giving low statistical power. The factors found to beFigure 1 Overall survival by tumour site (a), T-stage (b), LNR (c) and the
HPB 2016, 18, 332–338 © 2016 International Hepato-Psignificant in univariable analyses were then entered into
multivariable Cox regression models, with OS as the outcome
(Table 3). Fig. 1a–c shows the OS for components of the final
model, as well as the resulting risk score (Fig. 1d).
Pancreatoduodenectomy prognostic index (PPI)
Risk score for each of the variables is given in Table 4. To
calculate the PPI, the LNR should be multiplied by four, with the
result added to the sub-score for the site of primary tumour and
Tstage (PPI = 4 × LNR + Tumour site score + T stage score). For
example, a patient with T3 ampullary carcinoma and a LNR of
25% would have a PPI of: 2 + 3 + (0.25 × 4) = 6.
The PPI was then applied to the patients in the derivation
cohort, and ROC curves calculated for OS at both one and threecalculated Prognostic index (d)
ancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.












LNR 4× (individual LNR) Figure 2 Outcome based on the risk score calculated using the
Prognostic Index (dotted lines indicate 95% CI)
336 HPByears. This gave areas under the ROC curves (AUROCs) of 0.72
(95% CI: 0.67–0.76, p < 0.001) at one year and 0.77 (0.73–0.82
p < 0.001) at three years.
The PPI was then validated using an external cohort of 194
patients, the demographics of whom are reported in
Supplementary Table 1. The derivation and validation cohorts
were well matched on age and gender. However, the distributions
of both primary diagnosis and T-stages differed significantly
(p = 0.003, <0.001 respectively). Patients from the validation set
had significantly larger tumours (p = 0.001), with significantly
more nodes (p < 0.001) removed. However, the LNR (p = 0.583)
and OS (p = 0.584) were similar in the two groups.
After applying the PPI to this validation cohort, the resulting
AUROCs for survival were found to be significant (p < 0.001),
and similar to those in the derivation cohort, with 0.66 (95% CI:
0.57–0.75) for one year OS and 0.74 (0.65–0.82) at three years.
To illustrate the relationship between the PPI and patient out-
comes, binary logistic regression models were produced in the
validation cohort, with one and three year survival as outcomes,
and the PPI as a continuous covariate. The resulting models were
plotted (Fig. 2), with the PPI on the x-axis, and the predicted
survival rates on the y-axis. This plot can be used to convert a
patient’s score into a predicted survival rate.Discussion
This is an analysis of the clinico-pathological factors influencing
OS following PD. A prognostic index based upon tumour site,
tumour T stage and LNR was then developed to predict the
outcomes. The index was then successfully validated upon an
external patient cohort. The PI could be used in the pre- and
post-operative counselling of patients and its use could be
extended to research platforms. For the purpose of this study,
the influence of clinic-pathological factors that influence the
patient selection for PD (age, co-morbidities), post-operative
morbidity, the TNM status, LNR status, the tumour type and its
resectability (margin status) were assessed. The four commonHPB 2016, 18, 332–338 © 2016 International Hepato-Pperiampullary cancers are included and given different indi-
vidual risk scores accounting to the variations in their biological
behaviour.
Between these basic clinical, pathological variables and the
evolving cancer genetics there are several other factors such as
lymphovascular invasion and perineural invasion that are re-
ported to influence the survival.25,26 These variables are not
studied individually as the behaviour of the primary pathology
would significantly influence them and would create issues with
multi-collinearity as the prognostic index is developed. In terms
of considering tumour markers, CA 19.9 is sensitive in making
the diagnosis of patients with pancreatic cancer who are not
jaundiced but has not been consistent in assessing the overall
survival following PD for periampullary cancers27 and therefore
was also not included in the study.
Brennan et al.14 in the published normogram from MSKCC,
included adenocarcinoma of the head, body and tail of the
pancreas whereas the current proposed model can be used for all
the common tumour types of the head of the pancreas. In
addition, MSKCC model included the number of positive and
number of negative nodes but not the LNR, which is increasingly
accepted as an important prognostic indicator.14,21,22 While no
single prognostic index can include all the possible clinic-
pathological modifiable factors especially with the variations in
the tumour biology, it is important to identify and include the
most significant variables in a prognostic index with good pre-
dictive accuracy. The proposed Pancreaticoduodenectomy
Prognostic Index has been shown to be successful in estimating
the prognosis. Potential uses include counselling patients, opti-
mizing adjuvant therapeutic options and for risk stratification in
clinical trials.
One of the limitations of this study is the retrospective analysis
of the database. However, both institutions that provided the
patient cohorts employ prospective data collection. Also, it was
not possible to assess disease-specific survival (DSS), since cause
of death data were not available for a proportion of patients,ancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.
HPB 337despite cross checking outcomes with the national cancer registry
database. However, if it is assumed that deaths from other causes
are “random”, in that they are not influenced by the factors
considered (which would also have been an assumption if DSS
was analysed), then the relationships observed between factors
and OS should be comparable to those with DSS. The number of
patients with duodenal carcinoma in the study is suboptimal and
the prognostic index for this specific group needs further vali-
dation in larger multi-centre studies. Adjuvant chemotherapy did
not have a significant influence on outcomes in this study. There
appeared to be some benefit in the first year post-surgery (82%
vs. 67% survival), but by three years, survival was similar
whether or not it was used (40% vs. 41%) (p = 0.074). This could
be due to the inconsistency in the indications and type of
chemotherapy offered (based on 5FU, Irinotecan, Gemcitabine,
Capecitabine) over the years for the four subtypes of peri-
pancreatic cancers. Further variation in the practice was due to
difference in the time to receiving chemotherapy and the actual
numbers of cycles received.
This is one of the largest studies to assess the effects upon key
oncological outcomes of various clinical and pathological vari-
ables after PD. This study demonstrates the importance of the
LNR as a prognostic variable amongst common tumour types
and goes further to develop, and validate, a prognostic index
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